News & Updates
Filter by Specialty:
Lower all-cause death, fewer HF events with empagliflozin in acute HF
Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.
Lower all-cause death, fewer HF events with empagliflozin in acute HF
25 Jul 2024
Does salt intake truly affect outcomes in HF patients?
A small, single-centre study has suggested that increasing sodium intake does not affect weight or kidney function in patients hospitalized for acute heart failure (HF) who are undergoing aggressive diuretic therapy.
Does salt intake truly affect outcomes in HF patients?
25 Jul 2024
Increasing trend in DOAC-related intracerebral haemorrhage: How to improve outcomes?
New local findings presented at HKMF 2024 show an increasing trend in intracerebral haemorrhage (ICH) among patients on direct oral anticoagulants (DOACs) between 2013 and 2022. Early initiation of reversal agents may improve outcomes in select cases with DOAC-related ICH.
Increasing trend in DOAC-related intracerebral haemorrhage: How to improve outcomes?
01 Jul 2024
Impaired thyroid hormone sensitivity ups MACE risk in angiography patients
Euthyroid patients undergoing coronary angiography who have impaired sensitivity to thyroid hormone are at increased risks of major adverse cardiovascular events (MACE) and cardiovascular death, a recent study has shown.